Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at Zacks Research

Key Points

• Zacks Research upgraded Zealand Pharma A/S from a "strong sell" to a "hold" rating, indicating a shift in sentiment towards the stock.
• The company has attracted multiple upgrades from prominent firms, including strong-buy ratings from BNP Paribas, Wells Fargo, and Barclays.
• Despite missing earnings expectations, Zealand Pharma maintains a strong market position with a market cap of $4.87 billion and an average rating of "Strong Buy".

Zacks Research upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) from a strong sell rating to a hold rating in a report issued on Monday morning,Zacks.com reports.

Several other equities analysts have also recently issued reports on the company. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, July 1st. Finally, Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. Five investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Zealand Pharma A/S currently has an average rating of "Strong Buy".

Zealand Pharma A/S Stock Down 1.7%

OTCMKTS:ZLDPF traded down $1.24 during midday trading on Monday, reaching $72.07. The company had a trading volume of 122 shares, compared to its average volume of 161. The firm has a market capitalization of $5.12 billion, a price-to-earnings ratio of 5.06 and a beta of 0.73. The stock's fifty day simple moving average is $61.27 and its 200-day simple moving average is $65.40. Zealand Pharma A/S has a 12-month low of $49.98 and a 12-month high of $135.65. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%.The business had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. On average, sell-side analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.